...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Cancer research derailed by nearly two years due to COVID-19, scientists say.

That's what I keep hoping for! The Dutchman posted something about a four month target months ago, so maybe that helps to explain these small financings.

Share
New Message
Please login to post a reply